What are you looking for?

Need help finding what you are looking for? Contact Us

Compare

Free Samples

Home Market Research Reports Pharmaceutical

Prescription Drugs

PUBLISHER: 360iResearch | PRODUCT CODE: 1572200

PUBLISHER: 360iResearch | PRODUCT CODE: 1572200

BREO Ellipta Drugs Market by Disease Condition (Asthma, COPD), Component (Corticosteroid (ICS), Long-Acting Beta2-Adrenergic Agonist), End User, Distribution Channel - Global Forecast 2025-2030

PUBLISHED: October 15, 2024

PAGES: 191 Pages

DELIVERY TIME: 1-2 business days

ADD TO COMPARE

SELECT AN OPTION

List of Tables

The BREO Ellipta Drugs Market was valued at USD 3.05 billion in 2023, expected to reach USD 3.18 billion in 2024, and is projected to grow at a CAGR of 4.53%, to USD 4.16 billion by 2030.

The market for BREO Ellipta drugs, utilized primarily in treating chronic obstructive pulmonary disease (COPD) and asthma, is driven by a growing aging population, rising prevalence of respiratory ailments, and heightened awareness regarding early diagnosis and treatment. These medications provide a combination therapy approach of fluticasone and vilanterol, aimed at improving lung function and reducing exacerbations. The necessity for BREO Ellipta drugs stems from the increasing demand for effective, easy-to-use, and long-acting respiratory treatments. The major applications include symptom management in COPD and asthma, whereas end-use is concentrated in hospitals, clinics, and homecare settings. Key factors contributing to the growth of this market include technological advancements in drug delivery systems, supportive government regulations, and an expanding geriatric population more susceptible to respiratory diseases. Recent potential opportunities lie in extending application to pediatric care and exploiting telemedicine for remote patient monitoring. Expansion into emerging markets with unmet medical needs presents another opportunity. However, the market faces limiting factors, such as high treatment costs, side effects associated with corticosteroids, and competition from generic drug alternatives, which may restrain growth. Additionally, stringent regulatory environments and the essential requirement for clinical trials prolong market entry timelines. Areas for innovation and research prominently involve enhancing the efficacy of combination therapies, developing patient-centric inhalers, and integrating digital health technologies to improve compliance and outcomes. Understanding the biosimilars landscape, investing in strategies to reduce production costs, and acquisitions of local players can further bolster market presence. The nature of the BREO Ellipta market is moderately fragmented and competitive, emphasizing research and development activities to maintain a competitive edge in the ever-evolving pharmaceuticals landscape. By navigating regulatory pathways and building robust distribution networks, businesses can optimize their market position and leverage existing opportunities for substantial growth.

KEY MARKET STATISTICS
Base Year [2023]	USD 3.05 billion
Estimated Year [2024]	USD 3.18 billion
Forecast Year [2030]	USD 4.16 billion
CAGR (%)	4.53%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving BREO Ellipta Drugs Market

The BREO Ellipta Drugs Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

Market Drivers
- Rising prevalence of chronic respiratory diseases
- Enhancements in inhaler technology to improve dosing accuracy and patient comfort
- Improving healthcare infrastructure and access to medications in emerging markets
Market Restraints
- Adverse side effects and long-term safety concerns
Market Opportunities
- Developing partnerships with healthcare organizations to foster trust in BREO Ellipta among healthcare providers
- Development of combination therapies involving BREO ellipta for enhanced patient compliance
Market Challenges
- Complex and varying regulatory environments across different countries

Porter's Five Forces: A Strategic Tool for Navigating the BREO Ellipta Drugs Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the BREO Ellipta Drugs Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the BREO Ellipta Drugs Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the BREO Ellipta Drugs Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the BREO Ellipta Drugs Market

A detailed market share analysis in the BREO Ellipta Drugs Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the BREO Ellipta Drugs Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the BREO Ellipta Drugs Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the BREO Ellipta Drugs Market

A strategic analysis of the BREO Ellipta Drugs Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the BREO Ellipta Drugs Market, highlighting leading vendors and their innovative profiles. These include AstraZeneca plc, Boehringer Ingelheim International GmbH, CHIESI Farmaceutici S.p.A., Cipla Limited, GlaxoSmithKline plc, Hikma Pharmaceuticals PLC, Lupin Pharmaceuticals, Inc., Merck & Co., Inc., Novartis AG, Orion Corporation, and Teva Pharmaceutical Industries Ltd..

Market Segmentation & Coverage

This research report categorizes the BREO Ellipta Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

Based on Disease Condition, market is studied across Asthma and COPD.
Based on Component, market is studied across Corticosteroid (ICS) and Long-Acting Beta2-Adrenergic Agonist.
Based on End User, market is studied across Clinics, Homecare Settings, and Hospitals.
Based on Distribution Channel, market is studied across Online Sales and Pharmacies.
Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Product Code: MRR-81515600A1FD

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

5.1. Market Dynamics
- 5.1.1. Drivers
  - 5.1.1.1. Rising prevalence of chronic respiratory diseases
  - 5.1.1.2. Enhancements in inhaler technology to improve dosing accuracy and patient comfort
  - 5.1.1.3. Improving healthcare infrastructure and access to medications in emerging markets
- 5.1.2. Restraints
  - 5.1.2.1. Adverse side effects and long-term safety concerns
- 5.1.3. Opportunities
  - 5.1.3.1. Developing partnerships with healthcare organizations to foster trust in BREO Ellipta among healthcare providers
  - 5.1.3.2. Development of combination therapies involving BREO ellipta for enhanced patient compliance
- 5.1.4. Challenges
  - 5.1.4.1. Complex and varying regulatory environments across different countries
5.2. Market Segmentation Analysis
5.3. Porter's Five Forces Analysis
- 5.3.1. Threat of New Entrants
- 5.3.2. Threat of Substitutes
- 5.3.3. Bargaining Power of Customers
- 5.3.4. Bargaining Power of Suppliers
- 5.3.5. Industry Rivalry
5.4. PESTLE Analysis
- 5.4.1. Political
- 5.4.2. Economic
- 5.4.3. Social
- 5.4.4. Technological
- 5.4.5. Legal
- 5.4.6. Environmental

6. BREO Ellipta Drugs Market, by Disease Condition

6.1. Introduction
6.2. Asthma
6.3. COPD

7. BREO Ellipta Drugs Market, by Component

7.1. Introduction
7.2. Corticosteroid (ICS)
7.3. Long-Acting Beta2-Adrenergic Agonist

8. BREO Ellipta Drugs Market, by End User

8.1. Introduction
8.2. Clinics
8.3. Homecare Settings
8.4. Hospitals

9. BREO Ellipta Drugs Market, by Distribution Channel

9.1. Introduction
9.2. Online Sales
9.3. Pharmacies

10. Americas BREO Ellipta Drugs Market

10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States

11. Asia-Pacific BREO Ellipta Drugs Market

11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand
11.13. Vietnam

12. Europe, Middle East & Africa BREO Ellipta Drugs Market

12.1. Introduction
12.2. Denmark
12.3. Egypt
12.4. Finland
12.5. France
12.6. Germany
12.7. Israel
12.8. Italy
12.9. Netherlands
12.10. Nigeria
12.11. Norway
12.12. Poland
12.13. Qatar
12.14. Russia
12.15. Saudi Arabia
12.16. South Africa
12.17. Spain
12.18. Sweden
12.19. Switzerland
12.20. Turkey
12.21. United Arab Emirates
12.22. United Kingdom

13. Competitive Landscape

13.1. Market Share Analysis, 2023
13.2. FPNV Positioning Matrix, 2023
13.3. Competitive Scenario Analysis
- 13.3.1. Iconovo's development of inhaled GLP-1 receptor agonists options
- 13.3.2. FDA expands Breo Ellipta approval to children aged 5-17 for asthma maintenance
13.4. Strategy Analysis & Recommendation

Companies Mentioned

1. AstraZeneca plc
2. Boehringer Ingelheim International GmbH
3. CHIESI Farmaceutici S.p.A.
4. Cipla Limited
5. GlaxoSmithKline plc
6. Hikma Pharmaceuticals PLC
7. Lupin Pharmaceuticals, Inc.
8. Merck & Co., Inc.
9. Novartis AG
10. Orion Corporation
11. Teva Pharmaceutical Industries Ltd.

Product Code: MRR-81515600A1FD

LIST OF FIGURES

FIGURE 1. BREO ELLIPTA DRUGS MARKET RESEARCH PROCESS
FIGURE 2. BREO ELLIPTA DRUGS MARKET SIZE, 2023 VS 2030
FIGURE 3. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY DISEASE CONDITION, 2023 VS 2030 (%)
FIGURE 7. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY DISEASE CONDITION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 8. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY COMPONENT, 2023 VS 2030 (%)
FIGURE 9. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY COMPONENT, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 10. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY END USER, 2023 VS 2030 (%)
FIGURE 11. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 12. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
FIGURE 13. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 14. AMERICAS BREO ELLIPTA DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 15. AMERICAS BREO ELLIPTA DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 16. UNITED STATES BREO ELLIPTA DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 17. UNITED STATES BREO ELLIPTA DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 18. ASIA-PACIFIC BREO ELLIPTA DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 19. ASIA-PACIFIC BREO ELLIPTA DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA BREO ELLIPTA DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA BREO ELLIPTA DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 22. BREO ELLIPTA DRUGS MARKET SHARE, BY KEY PLAYER, 2023
FIGURE 23. BREO ELLIPTA DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

TABLE 1. BREO ELLIPTA DRUGS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. BREO ELLIPTA DRUGS MARKET DYNAMICS
TABLE 7. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY ASTHMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY COPD, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY CORTICOSTEROID (ICS), BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY LONG-ACTING BETA2-ADRENERGIC AGONIST, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY ONLINE SALES, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. AMERICAS BREO ELLIPTA DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
TABLE 21. AMERICAS BREO ELLIPTA DRUGS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 22. AMERICAS BREO ELLIPTA DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 23. AMERICAS BREO ELLIPTA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 24. AMERICAS BREO ELLIPTA DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 25. ARGENTINA BREO ELLIPTA DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
TABLE 26. ARGENTINA BREO ELLIPTA DRUGS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 27. ARGENTINA BREO ELLIPTA DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 28. ARGENTINA BREO ELLIPTA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 29. BRAZIL BREO ELLIPTA DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
TABLE 30. BRAZIL BREO ELLIPTA DRUGS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 31. BRAZIL BREO ELLIPTA DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 32. BRAZIL BREO ELLIPTA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 33. CANADA BREO ELLIPTA DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
TABLE 34. CANADA BREO ELLIPTA DRUGS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 35. CANADA BREO ELLIPTA DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 36. CANADA BREO ELLIPTA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 37. MEXICO BREO ELLIPTA DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
TABLE 38. MEXICO BREO ELLIPTA DRUGS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 39. MEXICO BREO ELLIPTA DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 40. MEXICO BREO ELLIPTA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 41. UNITED STATES BREO ELLIPTA DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
TABLE 42. UNITED STATES BREO ELLIPTA DRUGS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 43. UNITED STATES BREO ELLIPTA DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 44. UNITED STATES BREO ELLIPTA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 45. UNITED STATES BREO ELLIPTA DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 46. ASIA-PACIFIC BREO ELLIPTA DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
TABLE 47. ASIA-PACIFIC BREO ELLIPTA DRUGS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 48. ASIA-PACIFIC BREO ELLIPTA DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 49. ASIA-PACIFIC BREO ELLIPTA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 50. ASIA-PACIFIC BREO ELLIPTA DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 51. AUSTRALIA BREO ELLIPTA DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
TABLE 52. AUSTRALIA BREO ELLIPTA DRUGS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 53. AUSTRALIA BREO ELLIPTA DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 54. AUSTRALIA BREO ELLIPTA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 55. CHINA BREO ELLIPTA DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
TABLE 56. CHINA BREO ELLIPTA DRUGS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 57. CHINA BREO ELLIPTA DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 58. CHINA BREO ELLIPTA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 59. INDIA BREO ELLIPTA DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
TABLE 60. INDIA BREO ELLIPTA DRUGS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 61. INDIA BREO ELLIPTA DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 62. INDIA BREO ELLIPTA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 63. INDONESIA BREO ELLIPTA DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
TABLE 64. INDONESIA BREO ELLIPTA DRUGS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 65. INDONESIA BREO ELLIPTA DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 66. INDONESIA BREO ELLIPTA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 67. JAPAN BREO ELLIPTA DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
TABLE 68. JAPAN BREO ELLIPTA DRUGS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 69. JAPAN BREO ELLIPTA DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 70. JAPAN BREO ELLIPTA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 71. MALAYSIA BREO ELLIPTA DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
TABLE 72. MALAYSIA BREO ELLIPTA DRUGS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 73. MALAYSIA BREO ELLIPTA DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 74. MALAYSIA BREO ELLIPTA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 75. PHILIPPINES BREO ELLIPTA DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
TABLE 76. PHILIPPINES BREO ELLIPTA DRUGS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 77. PHILIPPINES BREO ELLIPTA DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 78. PHILIPPINES BREO ELLIPTA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 79. SINGAPORE BREO ELLIPTA DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
TABLE 80. SINGAPORE BREO ELLIPTA DRUGS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 81. SINGAPORE BREO ELLIPTA DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 82. SINGAPORE BREO ELLIPTA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 83. SOUTH KOREA BREO ELLIPTA DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
TABLE 84. SOUTH KOREA BREO ELLIPTA DRUGS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 85. SOUTH KOREA BREO ELLIPTA DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 86. SOUTH KOREA BREO ELLIPTA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 87. TAIWAN BREO ELLIPTA DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
TABLE 88. TAIWAN BREO ELLIPTA DRUGS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 89. TAIWAN BREO ELLIPTA DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 90. TAIWAN BREO ELLIPTA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 91. THAILAND BREO ELLIPTA DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
TABLE 92. THAILAND BREO ELLIPTA DRUGS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 93. THAILAND BREO ELLIPTA DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 94. THAILAND BREO ELLIPTA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 95. VIETNAM BREO ELLIPTA DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
TABLE 96. VIETNAM BREO ELLIPTA DRUGS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 97. VIETNAM BREO ELLIPTA DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 98. VIETNAM BREO ELLIPTA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 99. EUROPE, MIDDLE EAST & AFRICA BREO ELLIPTA DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
TABLE 100. EUROPE, MIDDLE EAST & AFRICA BREO ELLIPTA DRUGS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 101. EUROPE, MIDDLE EAST & AFRICA BREO ELLIPTA DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 102. EUROPE, MIDDLE EAST & AFRICA BREO ELLIPTA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 103. EUROPE, MIDDLE EAST & AFRICA BREO ELLIPTA DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 104. DENMARK BREO ELLIPTA DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
TABLE 105. DENMARK BREO ELLIPTA DRUGS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 106. DENMARK BREO ELLIPTA DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 107. DENMARK BREO ELLIPTA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 108. EGYPT BREO ELLIPTA DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
TABLE 109. EGYPT BREO ELLIPTA DRUGS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 110. EGYPT BREO ELLIPTA DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 111. EGYPT BREO ELLIPTA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 112. FINLAND BREO ELLIPTA DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
TABLE 113. FINLAND BREO ELLIPTA DRUGS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 114. FINLAND BREO ELLIPTA DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 115. FINLAND BREO ELLIPTA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 116. FRANCE BREO ELLIPTA DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
TABLE 117. FRANCE BREO ELLIPTA DRUGS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 118. FRANCE BREO ELLIPTA DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 119. FRANCE BREO ELLIPTA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 120. GERMANY BREO ELLIPTA DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
TABLE 121. GERMANY BREO ELLIPTA DRUGS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 122. GERMANY BREO ELLIPTA DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 123. GERMANY BREO ELLIPTA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 124. ISRAEL BREO ELLIPTA DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
TABLE 125. ISRAEL BREO ELLIPTA DRUGS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 126. ISRAEL BREO ELLIPTA DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 127. ISRAEL BREO ELLIPTA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 128. ITALY BREO ELLIPTA DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
TABLE 129. ITALY BREO ELLIPTA DRUGS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 130. ITALY BREO ELLIPTA DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 131. ITALY BREO ELLIPTA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 132. NETHERLANDS BREO ELLIPTA DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
TABLE 133. NETHERLANDS BREO ELLIPTA DRUGS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 134. NETHERLANDS BREO ELLIPTA DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 135. NETHERLANDS BREO ELLIPTA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 136. NIGERIA BREO ELLIPTA DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
TABLE 137. NIGERIA BREO ELLIPTA DRUGS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 138. NIGERIA BREO ELLIPTA DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 139. NIGERIA BREO ELLIPTA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 140. NORWAY BREO ELLIPTA DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
TABLE 141. NORWAY BREO ELLIPTA DRUGS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 142. NORWAY BREO ELLIPTA DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 143. NORWAY BREO ELLIPTA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 144. POLAND BREO ELLIPTA DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
TABLE 145. POLAND BREO ELLIPTA DRUGS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 146. POLAND BREO ELLIPTA DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 147. POLAND BREO ELLIPTA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 148. QATAR BREO ELLIPTA DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
TABLE 149. QATAR BREO ELLIPTA DRUGS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 150. QATAR BREO ELLIPTA DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 151. QATAR BREO ELLIPTA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 152. RUSSIA BREO ELLIPTA DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
TABLE 153. RUSSIA BREO ELLIPTA DRUGS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 154. RUSSIA BREO ELLIPTA DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 155. RUSSIA BREO ELLIPTA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 156. SAUDI ARABIA BREO ELLIPTA DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
TABLE 157. SAUDI ARABIA BREO ELLIPTA DRUGS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 158. SAUDI ARABIA BREO ELLIPTA DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 159. SAUDI ARABIA BREO ELLIPTA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 160. SOUTH AFRICA BREO ELLIPTA DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
TABLE 161. SOUTH AFRICA BREO ELLIPTA DRUGS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 162. SOUTH AFRICA BREO ELLIPTA DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 163. SOUTH AFRICA BREO ELLIPTA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 164. SPAIN BREO ELLIPTA DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
TABLE 165. SPAIN BREO ELLIPTA DRUGS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 166. SPAIN BREO ELLIPTA DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 167. SPAIN BREO ELLIPTA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 168. SWEDEN BREO ELLIPTA DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
TABLE 169. SWEDEN BREO ELLIPTA DRUGS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 170. SWEDEN BREO ELLIPTA DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 171. SWEDEN BREO ELLIPTA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 172. SWITZERLAND BREO ELLIPTA DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
TABLE 173. SWITZERLAND BREO ELLIPTA DRUGS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 174. SWITZERLAND BREO ELLIPTA DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 175. SWITZERLAND BREO ELLIPTA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 176. TURKEY BREO ELLIPTA DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
TABLE 177. TURKEY BREO ELLIPTA DRUGS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 178. TURKEY BREO ELLIPTA DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 179. TURKEY BREO ELLIPTA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 180. UNITED ARAB EMIRATES BREO ELLIPTA DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
TABLE 181. UNITED ARAB EMIRATES BREO ELLIPTA DRUGS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 182. UNITED ARAB EMIRATES BREO ELLIPTA DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 183. UNITED ARAB EMIRATES BREO ELLIPTA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 184. UNITED KINGDOM BREO ELLIPTA DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
TABLE 185. UNITED KINGDOM BREO ELLIPTA DRUGS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 186. UNITED KINGDOM BREO ELLIPTA DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 187. UNITED KINGDOM BREO ELLIPTA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 188. BREO ELLIPTA DRUGS MARKET SHARE, BY KEY PLAYER, 2023
TABLE 189. BREO ELLIPTA DRUGS MARKET, FPNV POSITIONING MATRIX, 2023